8 not yet recruiting, 1 completed. 8 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Not yet recruiting 8 |
| Phase 1 | 2 | Completed 1, Not yet recruiting 1 |
Follow NM8074: new trials by email Literature Review of NM8074 trials Research Report on NM8074
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN) NM8074 - IgA Nephropathy | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 10 | 2028-02-01 | 2026-04-13 |
| Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy NM8074 - aHUS - Atypical Hemolytic Uremic Syndrome | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 12 | 2027-11-01 | 2026-04-13 |
| Study of NM8074 in Adult C3 Glomerulopathy Patients NM8074 - C3 Glomerulopathy | Phase 1 / Phase 2 | Not yet recruiting | NovelMed Therapeutics | 18 | 2027-05-01 | 2026-04-13 |
| Study of NM8074 in Adult PNH Patients With Inadequate Response to Soliris NM8074, Soliris - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 12 | 2027-01-01 | 2026-04-13 |
| Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) NM8074, Placebo - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 12 | 2026-06-01 | 2025-03-11 |
| Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) NM8074 - PNH - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 6 | 2026-06-01 | 2025-03-30 |
| Study of NM8074 in Patients with Dermatomyositis (DM) NM8074 - Dermatomyositis | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 8 | 2026-06-01 | 2025-03-25 |
| Study of Efficacy and Safety of NM8074 in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy NM8074 - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 12 | 2026-04-01 | 2025-03-11 |
| First-in-Human (FIH) Clinical Study of NM8074 in Healthy Adult Volunteers NM8074, Placebo - Healthy | Phase 1 | Completed | NovelMed Therapeutics | 40 | 2020-08-12 | 2022-12-08 |
Hemoglobinuria, Paroxysmal (3) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Atypical Hemolytic Uremic Syndrome (1) · Dermatomyositis (1) · Glomerulonephritis, IGA (1)
United States (1)